NANJING KING-FRIEND BIOCHEMICAL PHARMACEUTICAL CO.,LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 13.39 CNY | -2.41% |
|
-0.52% | -10.73% |
| May. 13 | NKFPharma's Unit Gets FDA's Nod to Market Eptifibatide Injection in US | MT |
| May. 01 | NKFPharma Gets Nod to Register New Cancer Treatment | MT |
Evolution of the average Target Price on Nanjing King-Friend Biochemical Pharmaceutical Co.,Ltd.
Price target over the last 5 years
History of analyst recommendation changes
e8290487fc260be500639b89d1edfe3a.H7g0RGx8yKxHUW7Yl9zfJ_9upXLkB7vzbs-utQ0HBRQ.S9NnMAtOp-0jHFqx8Zvqccw00zqwTvzGJIrczXVUUndz3nNyNQ_lwyYSXg~433c140547b07ecef1ddddb6b1e98433
Analysts' Consensus
Sell
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
13.39
CNY
Average target price
15.82
CNY
Spread / Average Target
+18.11%
High Price Target
16
CNY
Spread / Highest target
+19.49%
Low Price Target
15.63
CNY
Spread / Lowest Target
+16.73%
Consensus detail
Consensus revision (last 18 months)
Trading Rating
Investor Rating
ESG Refinitiv
D
EPS Revisions
Annual profits - Rate of surprise
- Stock Market
- Equities
- 603707 Stock
- Consensus Nanjing King-Friend Biochemical Pharmaceutical Co.,Ltd.
